Malignant ascites

British Journal of Surgery

Volumn 83, Issue 1, 1996, Pages 6-14

  Parsons, S L ^a   Watson, S A ^a   Steele, R J C ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUMETANIDE; DIURETIC AGENT; FUROSEMIDE;

ASCITES TUMOR; CYTOLOGY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOLOGY; REVIEW; SURGICAL TECHNIQUE;

ABDOMINAL NEOPLASMS; ASCITES; FEMALE; HUMANS; MALE;

EID: 0030030780     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800830104     Document Type: Review

References (92)

1. Runyon BA. Care of patients with ascites. N Engl J Med 1994; 330: 337-42.
2. Garrison RN, Kaelin LD, Galloway RH, Heuser LS. Malignant ascites. Clinical and experimental observations. Ann Surg 1986; 203: 644-51.
3. Hird V, Thomas H, Stewart JSW, Epenetos AA. Malignant ascites: review of the literature, and an update on monoclonal antibody-targeted therapy. Eur J Obstet Gynecol Reprod Biol 1989; 32: 37-45.
4. Ringenberg QS, Doll DC, Loy TS, Yarbro JW. Malignant ascites of unknown origin. Cancer 1989; 64: 753-5.
5. Malik I, Abubakar S, Rizwana I, Alam F, Rizvi J, Khan A. Clinical features and management of malignant ascites. Journal of the Pakistan Medical Association (Karachi) 1991; 41: 38-40.
6. 32P) colloidal suspension therapy. Cancer 1981; 48: 2596-8.
7. Ariel IM, Orepeza R, Pack GT. Intracavitary administration of radioactive isotopes in the control of effusions due to cancer. Results in 267 patients. Cancer 1966; 19: 1096-102.
8. Hirabayshi K, Graham J. Genesis of ascites in ovarian carcinoma. Am J Obstet Gynecol 1970; 106: 492-7.
9. Kruger S, Greve D, Schueler FW. The absorption of fluid from the peritoneal cavity. Arch Int Pharmacodyn Ther 1962; 137: 173-8.
10. Rusznyak I, Foldi M, Szabo G. Lymphatics and Lymph Circulation: Physiology and Pathology. 2nd ed. New York: Pergamon Press, 1967.
11. Raybuck HE, Allen L, Harms SW. Absorption of serum from the peritoneal cavity. Am J Physiol 1960; 199: 1021-4.
12. Allen L, Raybuck HE. The effects of obliteration of the diaphragmatic lymphatic plexus on serous fluid. Anat Rec 1960; 137: 25-32.
13. Holm-Nielson P. Pathogenesis of ascites in peritoneal carcinomatosis. APMIS 1953; 33: 10-21.
14. Feldman GB, Knapp RC, Order SE, Hellman S. The role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma. Cancer Res 1972; 32: 1663-6.
15. Nagy JA, Herzberg KT, Dvorak JM, Dvorak HF. Pathogenesis of malignant ascites formation: initiating events that lead to fluid accumulation. Cancer Res 1993; 53: 2631-43.
16. Zink J, Greenway CV. Control of ascites absorption in anesthetized cats: effects of intraperitoneal pressure, protein, and furosemide diuresis. Gastroenterology 1977; 73: 1119-24.
17. Coates G, Bush RS, Aspin N. A study of ascites using lymphoscintigraphy with 99m Tc-sulfur colloid. Radiology 1973; 107: 577-83.
18. Tator CH, Olszewski J. Factors responsible for the distribution of radioactivity in a mouse glioma and brain after injection of radioiodinated human serum albumin (RIHSA). Cancer Res 1966; 26: 1569-81.
19. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumour cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-5.
20. Yeo K-T, Wang H, Nagy JA, Senger DR, Dvorak HF, Yeo T-K. Vascular permeability factor levels in line 1 and line 10 ascites tumors and human fluids. J Cell Biol 1991; 115 (Suppl): 421a (Abstract).
21. Zink J, Greenway CV. Intraperitoneal pressure in formation and reabsorption of ascites in cats. Am J Physiol 1977; 233: H185-90.
22. Bosch J, Arroyo V, Betriu A et al. Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 1980; 78: 92-9.
23. Greenway B, Johnson PJ, Williams R. Control of malignant ascites with spironolactone. Br J Surg 1982; 69: 441-2.
24. Pockros PJ, Esrason KT, Nguyen C, Duque J, Woods S. Mobilization of malignant ascites with diuretics is dependent on ascitic fluid characteristics. Gastroenterology 1992; 103: 1302-6.
25. Williams JW Jr, Simel DL. Does this patient have ascites? How to divine fluid in the abdomen. JAMA 1992; 267: 2645-8.
26. Beatty JD, Romero C, Brown PW, Lawrence W Jr, Terz JJ. Clinical value of carcinoembryonic antigen: diagnosis, prognosis, and follow-up of patients with cancer. Arch Surg 1979; 114: 563-7.
27. Bast RC Jr, Klug TL, St John E et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983; 309: 883-7.
28. Herbst AL. The epidemiology of ovarian carcinoma and the current status of tumor markers to detect disease. Am J Obstet Gynecol 1994; 170: 1099-105.
29. Buscarini L, Fonari F, Caneletti R et al. Diagnostic aspects and follow-up of 174 cases of hepatocellular carcinoma. Second report. Oncology 1991; 48: 26-30.
30. Cottone M, Turri M, Caltagirone M et al. Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and alphafetoprotein: a prospective study. Hepatogastroenterology 1988; 35: 101-3.
31. Goldberg BB, Goodman GA, Clearfield HR. Evaluation of ascites by ultrasound. Radiology 1970; 96: 15-22.
32. Wall SD, Hricak H, Bailey GD, Kerlan RK Jr, Goldberg HI, Higgins CB. MR imaging of pathologic abdominal fluid collections. J Comput Assist Tomogr 1986; 10: 746-50.
33. Schreve RH, Terpstra OT, Ausema L, Lameris JS, van Seijen AJ, Jeekel J. Detection of liver metastases. A prospective study comparing liver enzymes, scintigraphy, ultrasonography and computed tomography. Br J Surg 1984; 71: 947-9.
34. Vlachos L, Trakadas S, Gouliamos A et al. Comparative study between ultrasound, computed tomography, intra-arterial digital subtraction angiography, and magnetic resonance imaging in the differentiation of tumors of the liver. Gastrointestinal Radiology 1990; 15: 102-6.
35. Kramer BS, Gohagan J, Prorok PC, Smart C. A national cancer institute sponsored screening trial for prostatic, lung, colorectal, and ovarian cancers. Cancer 1992; 71 (Suppl): 589-93.
36. Reuter KL, Griffin T, Hunter RE. Comparison of abdominopelvic computed tomography results and findings at second-look laparotomy in ovarian carcinoma patients. Cancer 1989; 63: 1123-8.
37. Ellis P, Cunningham D. Management of carcinomas of the upper gastrointestinal tract. BMJ 1994; 308: 834-8.
38. Halvorsen RA Jr, Thompson WM. Primary neoplasms of the hollow organs of the gastrointestinal tract. Staging and follow-up. Cancer 1991; 67 (Suppl): 1181-8.
39. Runyon BA, Hoefs JC, Morgan TR. Ascitic fluid analysis in malignancy-related ascites. Hepatology 1988; 8: 1104-9.
40. Castaldo G, Oriani G, Cimino L et al. Total discrimination of peritoneal malignant ascites from cirrhosis- and hepatocarcinoma-associated ascites by assays of ascitic cholesterol and lactate dehydrogenase. Clin Chem 1994; 40: 478-83.
41. Colli A, Buccino G, Cocciolo M, Parravicini R, Mariani F, Scaltrini G. Diagnostic accuracy of sialic acid in the diagnosis of malignant ascites. Cancer 1989; 63: 912-16.
42. Scholmerich J, Volk BA, Kottgen E, Ehlers S, Gerok W. Fibronectin concentration in ascites differentiates between malignant and nonmalignant ascites. Gastroenterology 1984; 87: 1160-4.
43. Scholmerich J, Zimmermann U, Kottgen E, Volk BA, Ehlers S, Gerok W. Proteases and antiproteases related to the coagulation system in plasma and ascites - an approach to differentiate between malignant and cirrhotic ascites. Klinische Wochenschrift 1987; 65: 634-8.
44. Colli A, Buccino G, Cocciolo M, Parravicini R, Mariani F, Scaltrini G. Diagnostic accuracy of fibronectin in the differential diagnosis of ascites. Cancer 1986; 58: 2489-93.
45. Chu C-M, Lin S-M, Peng S-M, Wu C-S, Liaw Y-F. The role of laparoscopy in the evaluation of ascites of unknown origin. Gastrointest Endosc 1994; 40: 285-9.
46. Menzies RI, Fitzgerald JM, Mulpeter K. Laparoscopic diagnosis of ascites in Lesotho. BMJ 1985; 291: 473-5.
47. Lewis A, Archer TJ. Laparoscopy in general surgery. Br J Surg 1981; 68: 778-80.
48. Wexner SD, Cohen SM. Port site metastases after laparoscopic colorectal surgery for cure of malignancy. Br J Surg 1995; 82: 295-8.
49. Gleeson NC, Nicosia SV, Mark JE, Hoffman MS, Cavanagh D. Abdominal wall metastases from ovarian cancer after laparoscopy. Am J Obstet Gynecol 1993; 169: 522-3.
50. Ross GJ, Kessler HB, Clair MR, Gatenby RA, Hartz WH, Ross LV. Sonographically guided paracentesis for palliation of symptomatic malignant ascites. AJR Am J Roentgenol 1989; 153: 1309-11.
51. Appelqvist P, Silvo J, Salmela L, Kostianen S. On the treatment and prognosis of malignant ascites: is the survival time determined when the abdominal paracentesis is needed? J Surg Oncol 1982; 20: 238-42.
52. Gines P, Tito L, Arroyo V et al. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-502.
53. Arroyo V, Gines P, Planas R. Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis. (Review). Gastroenterol Clin North Am 1992; 21: 237-56.
54. Gough IR, Balderson GA. Malignant ascites: a comparison of peritoneovenous shunting and nonoperative management. Cancer 1993; 71: 2377-82.
55. Torisu M, Katano M, Kimura Y, Itoh H, Takesue M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 1983; 93: 357-64.
56. Perez-Ayuso R, Arroyo V, Planas R et al. Randomized comparative study of efficacy of frusemide versus spironolactone in nonazotemic cirrhosis with ascites. Relationship between the diuretic response and the activity of the renin-aldosterone system. Gastroenterology 1983; 84: 961-8.
57. Razis DV, Athanasiou A, Dadiotis L. Diuretics in malignant effusions and edemas of generalized cancer. J Med 1976; 7: 449-61.
58. Richardson GS, Scully RE, Nikrui N, Nelson JH Jr. Common epithelial cancer of the ovary part 1. N Engl J Med 1985; 312: 415-24.
59. Richardson GS, Scully RE, Nikrui N, Nelson JH Jr. Common epithelial cancer of the ovary part 2. N Engl J Med 1985; 312: 474-83.
60. Speyer JL, Collins JM, Dedrick RL et al. Phase 1 and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res 1980; 40: 567-72.
61. Rosenshein N, Blake D, McIntyre PA et al. The effect of volume on the distribution of substances instilled into the peritoneal cavity. Gynecol Oncol 1978; 6: 106-10.
62. Markman M. Intraperitoneal chemotherapy as a treatment of ovarian carcinoma: why, how, and when? Obstet Gynecol Surv 1987; 42: 533-9.
63. Cunliffe WJ, Sugarbaker PH. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br J Surg 1989; 76: 1082-90.
64. Hagiwara A, Takahashi T, Kojima O et al. Prophylaxis with carbon-absorbed mitomycin against peritoneal recurrence of gastric cancer. Lancet 1992; 339: 629-31.
65. Jones A, Trott P, Cunningham D et al. A pilot study of intraperitoneal cisplatin in the management of gastric cancer. Ann Oncol 1994; 5: 123-6.
66. Schilsky RL, Choi KE, Grayhack J, Grimmer D, Guarnieri C, Fullem L. Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer. J Clin Oncol 1990; 8: 2054-61.
67. Bitran J. Intraperitoneal bleomycin. Pharmacokinetics and results of a phase II trial. Cancer 1985; 56: 2420-3.
68. Müller JH. Über die Verwendung von küntslichen radioactiven Isotopen zur Erzielung von lokalisierten biologischen Strahlenwirkugen. Experientia 1945; 1: 199-200.
69. Walton LA, Yudusky A, Rubenstein L, Roth LM, Young RC. Stage II carcinoma of the ovary: an analysis of survival after comprehensive surgical staging and adjuvant therapy. Gynecol Oncol 1992; 44: 55-60.
70. Peters WA 3rd, Smith MR, Cain JM, Lee RB, Yon J Jr. Intraperitoneal P-32 is not an effective consolidation therapy after a negative second look laparotomy for epithelial carcinoma of the ovary. Gynecol Oncol 1992; 47: 146-9.
71. Helzberg JH, Greenberger NJ. Peritoneovenous shunts in malignant ascites. Dig Dis Sci 1985; 30: 1104-7.
72. Qazi R, Savlov ED. Peritoneovenous shunt for palliation of malignant ascites. Cancer 1982; 49: 600-2.
73. Edney JA, Hill A, Armstrong D. Peritoneovenous shunts palliate malignant ascites. Am J Surg 1989; 158: 598-601.
74. Fulenwider J, Galambos J, Smith R, Henderson J, Warren W. LeVeen vs Denver peritoneovenous shunts for intractable ascites of cirrhosis. Arch Surg 1986; 121: 351-5.
75. Scott Coombes DM, Whawell SA, Vipond MN, Crnonevic L, Thompson JN. Fibrinolytic activity of ascites caused by alcoholic cirrhosis and peritoneal malignancy. Gut 1993; 34: 1120-2.
76. Lacy JH, Wieman TJ, Shively EH. Management of malignant ascites. Surg Gynecol Obstet 1984; 159: 397-412.
77. Fildes J, Narvaez GP, Baig KA, Pai N, Gerst PH. Pulmonary tumor embolization after peritoneovenous shunting for malignant ascites. Cancer 1988; 61: 1973-6.
78. Souter RG, Tarin D, Kettlewell MG. Peritoneovenous shunts in the management of malignant ascites. Br J Surg 1983; 70: 478-81.
79. Katano M, Torisu M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. II. Intraperitoneal inflammatory cell-mediated tumor cell destruction. Surgery 1983; 93: 365-73.
80. Kato H, Yamamura Y, Kin R et al. Treatment of malignant ascites and pleurisy by a streptococcal preparation OK-432 with fresh frozen plasma - a mechanism of polymorphonuclear leukocyte (PMN) accumulation. Int J Immunopharmacol 1989; 11: 117-28.
81. Kitsuki H, Uchiyama A, Yoshida T, Torisu M. OK-432 induced enhancement of ICAM-1 expression on tumor cells positively correlates to therapeutic effects for malignant effusion. Clin Immunol Immunopathol 1994; 71: 89-95.
82. Koelbl H, Micksche M, Gitsch G, Hanzal E, Nowotny C. Treatment with biologic response modifiers in patients with ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1991; 41: 64-9.
83. Buckman R, De Angelis C, Shaw P et al. Intraperitoneal therapy of malignant ascites associated with carcinoma of ovary and breast using radioiodinated monoclonal antibody 2G3. Gynecol Oncol 1992; 47: 102-9.
84. D'Errico A, Garbisa S, Liotta L, Castronovo V, Stetler-Stevenson WG, Grigioni WF. Augmentation of type IV collagenase, laminin receptor and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod Pathol 1991; 4: 239-46.
85. Zucker S, Lysik RM, Zarrabi MH, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993; 53: 140-6.
86. Hewitt RE, Leach IH, Powe DG, Clark IM, Cawston TE, Turner DR. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int J Cancer 1991; 49: 666-72.
87. Reich R, Thompson EW, Iwamoto Y et al. Effects of inhibitors of plasminogen activator, serine proteinases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 1988; 48: 3307-12.
88. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701-8.
89. Davies B, Miles DW, Happerfield LC et al. Activity of type IV collagenases in benign and malignant breast disease. Br J Cancer 1993; 67: 1126-31.
90. Watson S, Morris T, Robinson G, Crimmin M, Brown P, Hardcastle J. Inhibition of organ invasion by the matrix metalloproteinase inhibitor, Batimastat (BB-94) in two human colon carcinoma metastasis models. Cancer Res 1995; 55: 3629-33.
91. Folkman J. Tumor angiogenesis. Adv Cancer Res 1985; 43: 175-203.
92. Macaulay V, O'Byrne K, Saunders M et al. Phase I study of the matrix metalloproteinase inhibitor Batimastat (BB-94) in patients with pleural effusions. Br J Cancer 1995; 71: 11 (Abstract).